StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
11
Publishing Date
2023 - 10 - 17
1
2023 - 04 - 17
1
2023 - 01 - 30
1
2022 - 10 - 24
1
2022 - 08 - 04
1
2022 - 06 - 22
1
2022 - 04 - 11
1
2022 - 03 - 29
1
2021 - 12 - 09
1
2021 - 11 - 29
1
2021 - 11 - 08
1
Sector
Consumer non-durables
11
Energy minerals
1
Health technology
4
Industrial services
1
Manufacturing
11
Tags
Acquire
8
Acquisition
27
Agreement
15
America
13
Biotech-bay
11
Brands
11
Business
12
Cancer
9
Cel
8
Ces
9
Collaboration
7
Commercial
7
Companies
11
Conference
10
Disease
11
Energy
44
Europe
15
Expansion
8
Expected
9
Fashion
13
Fda
8
Financial
30
Global
49
Group
27
Growing
14
Growth
87
Health
10
Insurance
9
International
13
Management
16
Marine
9
Maritime
11
Market
179
N/a
1064
Offering
13
One
8
Partnership
21
Platform
16
Pneumococcal
14
Positive
11
Potential
8
Program
14
Report
53
Research
37
Results
77
Retail
8
Sales
10
Security
8
Services
11
Set
10
Solutions
11
Study
14
Technology
13
Therapeutics
12
Total
12
Trends
10
Trust
10
Update
13
Vax-24
11
Year
17
Entities
Apellis pharmaceuticals, inc.
1
Delek logistics partners, l.p.
1
Delek us holdings, inc.
1
Kering
11
Sutro biopharma, inc.
3
Vaxcyte, inc.
3
Symbols
ABBV
31
ADIL
10
ALNY
19
ALPMF
14
ALPMY
14
AMGN
14
ANVS
10
AQST
18
ARVL
21
AZN
13
BBIO
16
BGNE
19
BIIB
13
BMY
27
BNTX
17
BYSI
11
CHRS
21
CLDX
10
CLSD
15
DARE
13
FBIO
10
FNCTF
21
GILD
13
GSK
12
HOTH
14
IMMP
11
IMMX
10
INCY
15
IONS
21
IT
12
JNJ
46
LLY
30
LTUM
14
MDWD
11
MRK
19
MS
10
MYOV
10
NDAQ
42
NVS
19
NVSEF
15
PFE
45
PLRX
10
PPRUF
11
PPRUY
11
RCKT
11
RDHL
10
REGN
26
RGNX
17
RNAZ
10
SCYX
11
SLS
11
SNY
103
SNYNF
79
SRNE
19
TAK
14
TAYD
17
TEVJF
14
TNXP
12
VERU
10
VRTX
11
Exchanges
Nasdaq
11
Nyse
1
Crawled Date
2023 - 10 - 17
1
2023 - 04 - 17
1
2023 - 01 - 30
1
2022 - 10 - 24
1
2022 - 08 - 04
1
2022 - 06 - 22
1
2022 - 04 - 11
1
2022 - 03 - 29
1
2021 - 12 - 09
1
2021 - 11 - 29
1
2021 - 11 - 08
1
Crawled Time
08:00
1
09:00
1
10:00
1
11:00
3
13:00
1
14:20
1
17:00
3
Source
www.biospace.com
7
www.globenewswire.com
3
www.prnewswire.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Positive
symbols :
Ppruy
save search
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
Published:
2023-10-17
(Crawled : 11:00)
- globenewswire.com
PPRUF
|
$358.55
37.56%
1.5K
|
Consumer Non-Durables
|
-17.38%
|
O:
-1.4%
H:
2.43%
C:
0.02%
PPRUY
|
$36.0023
-0.11%
220K
|
Manufacturing
|
-16.71%
|
O:
-2.01%
H:
2.36%
C:
1.96%
APLS
G
|
$47.53
0.04%
0.04%
1.2M
|
Health Technology
|
-1.35%
|
O:
0.66%
H:
1.2%
C:
-3.55%
kidney
positive
week
results
Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies
Published:
2023-04-17
(Crawled : 11:00)
- globenewswire.com
PPRUF
|
$358.55
37.56%
1.5K
|
Consumer Non-Durables
|
-42.51%
|
O:
0.05%
H:
1.69%
C:
-1.81%
PPRUY
|
$36.0023
-0.11%
220K
|
Manufacturing
|
-43.14%
|
O:
-2.08%
H:
0.03%
C:
-0.19%
PCVX
|
$60.82
0.33%
0.33%
1.3M
|
Health Technology
|
66.66%
|
O:
15.18%
H:
6.42%
C:
0.71%
STRO
|
$3.635
-3.58%
-3.71%
520K
|
Health Technology
|
-17.5%
|
O:
0.68%
H:
8.13%
C:
5.64%
vax-24
pneumococcal
vaccine
positive
study
phase 2
Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM•854 Clinical Study, Against High Blood Pressure
Published:
2023-01-30
(Crawled : 17:00)
- biospace.com/
PPRUF
|
$358.55
37.56%
1.5K
|
Consumer Non-Durables
|
-40.93%
|
O:
1.84%
H:
0.26%
C:
-1.13%
PPRUY
|
$36.0023
-0.11%
220K
|
Manufacturing
|
-40.52%
|
O:
0.25%
H:
1.36%
C:
0.69%
blood
positive
results
Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
Published:
2022-10-24
(Crawled : 11:00)
- biospace.com/
PPRUF
|
$358.55
37.56%
1.5K
|
Consumer Non-Durables
|
-19.3%
|
O:
0.55%
H:
3.41%
C:
-0.9%
PPRUY
|
$36.0023
-0.11%
220K
|
Manufacturing
|
-20.16%
|
O:
-0.01%
H:
0.83%
C:
-0.01%
PCVX
|
$60.82
0.33%
0.33%
1.3M
|
Health Technology
|
195.58%
|
O:
70.8%
H:
2.7%
C:
-6.12%
STRO
|
$3.635
-3.58%
-3.71%
520K
|
Health Technology
|
-35.64%
|
O:
0.71%
H:
14.96%
C:
13.91%
candidate
disease
topline
vaccine
positive
study
pneumococcal
Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs
Published:
2022-08-04
(Crawled : 17:00)
- biospace.com/
PPRUF
|
$358.55
37.56%
1.5K
|
Consumer Non-Durables
|
-35.09%
|
O:
0.0%
H:
5.96%
C:
2.52%
PPRUY
|
$36.0023
-0.11%
220K
|
Manufacturing
|
-35.91%
|
O:
0.04%
H:
1.21%
C:
0.78%
PCVX
|
$60.82
0.33%
0.33%
1.3M
|
Health Technology
|
148.39%
|
O:
1.43%
H:
3.54%
C:
3.14%
STRO
|
$3.635
-3.58%
-3.71%
520K
|
Health Technology
|
-32.4%
|
O:
1.68%
H:
1.28%
C:
0.55%
vax-24
positive
Athira Puts Positive Spin on Alzheimer’s Trial Despite Missed Endpoint
Published:
2022-06-22
(Crawled : 14:20)
- biospace.com/
PPRUF
|
$358.55
37.56%
1.5K
|
Consumer Non-Durables
|
-28.76%
|
O:
-0.6%
H:
5.96%
C:
1.4%
PPRUY
|
$36.0023
-0.11%
220K
|
Manufacturing
|
-30.72%
|
O:
-2.59%
H:
2.19%
C:
1.04%
trial
alzheimer’s
positive
alzheimer's
Delek Logistics Partners, LP Announces Acquisition of 3Bear Energy Increasing its Prominent Position in the Permian Basin
Published:
2022-04-11
(Crawled : 13:00)
- prnewswire.com
PPRUF
|
$358.55
37.56%
1.5K
|
Consumer Non-Durables
|
-39.36%
|
O:
-2.37%
H:
3.76%
C:
0.53%
PPRUY
|
$36.0023
-0.11%
220K
|
Manufacturing
|
-39.42%
|
O:
-1.49%
H:
0.09%
C:
-1.55%
DK
4
|
$29.67
0.75%
0.0%
530K
|
Energy Minerals
|
31.69%
|
O:
-0.93%
H:
1.12%
C:
-1.61%
DKL
|
$38.42
1.11%
0.16%
100K
|
Industrial Services
|
-19.15%
|
O:
0.93%
H:
3.0%
C:
0.6%
acquisition
energy
positive
Valbiotis Announces the Positive Results of Its Clinical Study on the Bioavailability and Mode of Action of TOTUM•070, Against Hypercholesterolemia
Published:
2022-03-29
(Crawled : 09:00)
- biospace.com/
PPRUF
|
$358.55
37.56%
1.5K
|
Consumer Non-Durables
|
-43.11%
|
O:
4.54%
H:
4.11%
C:
-1.36%
PPRUY
|
$36.0023
-0.11%
220K
|
Manufacturing
|
-44.53%
|
O:
3.52%
H:
0.48%
C:
-1.08%
positive
results
hypercholesterolemia
iOnctura Presents Positive Clinical Data At ESMO-IO Supporting Advancement of IOA-289, a Novel Autotaxin Inhibitor, Into Phase Ib Pancreatic Cancer Studies
Published:
2021-12-09
(Crawled : 08:00)
- biospace.com/
PPRUF
|
$358.55
37.56%
1.5K
|
Consumer Non-Durables
|
-57.07%
|
O:
-6.26%
H:
4.62%
C:
0.72%
PPRUY
|
$36.0023
-0.11%
220K
|
Manufacturing
|
-55.9%
|
O:
-2.24%
H:
0.01%
C:
-0.69%
ioa-289
xin
positive
cancer
pancreatic
Ayurcann Holdings Corp. Reports Third Consecutive Quarter of Positive Operating Income
Published:
2021-11-29
(Crawled : 17:00)
- globenewswire.com
PPRUF
|
$358.55
37.56%
1.5K
|
Consumer Non-Durables
|
-52.77%
|
O:
0.14%
H:
4.98%
C:
2.88%
PPRUY
|
$36.0023
-0.11%
220K
|
Manufacturing
|
-51.93%
|
O:
3.3%
H:
0.39%
C:
0.17%
positive
iOnctura Clinical Expansion Positions Lead PI3Kδ Inhibitor IOA-244 for Potential Registration Studies in Metastatic Uveal Melanoma
Published:
2021-11-08
(Crawled : 10:00)
- biospace.com/
PPRUF
|
$358.55
37.56%
1.5K
|
Consumer Non-Durables
|
-53.5%
|
O:
-0.16%
H:
0.52%
C:
0.28%
PPRUY
|
$36.0023
-0.11%
220K
|
Manufacturing
|
-52.71%
|
O:
1.09%
H:
0.21%
C:
-0.16%
potential
expansion
positive
Gainers vs Losers
67%
33%
Top 10 Gainers
AGBA
|
News
|
$1.26
215.0%
68.25%
130M
|
Finance
EGOX
|
$0.0515
43.06%
30.1%
330M
|
OLB
4
|
$0.33
-14.95%
25.53%
840K
|
Technology Services
NVFY
|
$2.77
31.28%
23.83%
33M
|
Consumer Durables
ZCMD
|
$1.87
28.97%
22.46%
31M
|
Commercial Services
RCON
|
$0.1112
13.01%
21.28%
1.7M
|
Distribution Services
INSG
|
$3.03
25.21%
20.13%
330K
|
Electronic Technology
GCTK
|
$0.8191
22.25%
18.2%
190K
|
Manufacturing
WLGS
|
$0.59
18.0%
17.9%
2.3M
|
ASNS
|
$0.828
21.75%
17.86%
18K
|
Your saved searches
Save your searches and get alerts when important news are released.